NICE recommends Roche’s Tecentriq in ES-SCLC following price rethinkNICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell Share XNICE recommends Roche’s Tecentriq in ES-SCLC following price rethinkhttps://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/
Merck & Co’s Keytruda produces mixed results in SCLCMerck & Co’s Keytruda immunotherapy has produced mixed results in a phase 3 trial testing it in first-line Share XMerck & Co’s Keytruda produces mixed results in SCLChttps://pharmaphorum.com/news/merck-cos-keytruda-produces-mixed-results-in-sclc/
PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedinSpain’s PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin Share XPharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedinhttps://pharmaphorum.com/news/pharmamar-and-jazz-sign-1bn-us-deal-for-lung-cancer-drug/
AbbVie axes multi-billion cancer flop Rova-T after another trial failsAbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is Share XAbbVie axes multi-billion cancer flop Rova-T after another trial failshttps://pharmaphorum.com/news/abbvie-axes-multi-billion-cancer-flop-rova-t-after-another-trial-fails/
Opdivo and Keytruda approved in new lung cancer usesThe FDA has approved Merck’s Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer Share XOpdivo and Keytruda approved in new lung cancer useshttps://pharmaphorum.com/news/bmss-opdivo-approved-lung-cancer/
